Ensitimib for use in the treatment of chronic obstructive pulmonary disease (COPD)

Encerfentin provides a safe and effective treatment for COPD patients with a blood eosinophil count of less than 300 cells/μL via inhalation, addressing the problem of poor efficacy of existing therapies and significantly reducing the frequency and severity of COPD exacerbations.

CN122121878APending Publication Date: 2026-05-29VERONA PHARMACEUTICALS LTD
View PDF 2 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
VERONA PHARMACEUTICALS LTD
Filing Date
2024-09-05
Publication Date
2026-05-29

AI Technical Summary

Technical Problem

Current treatments are ineffective for COPD patients with a blood eosinophil count of less than 300 cells/μL, especially the triple combination therapy of long-acting muscarinic antagonists, long-acting β2-agonists, and inhaled corticosteroids, which has failed to meet efficacy and safety requirements.

Method used

Encerfentin, a PDE3/PDE4 inhibitor, is administered to patients via inhalation. It combines anti-inflammatory and bronchodilatory activities to treat COPD patients with a blood eosinophil count of less than 300 cells/μL.

Benefits of technology

It significantly reduces the frequency and severity of COPD exacerbations, prolongs the duration of exacerbations, reduces the risk of exacerbations, and provides a safe and effective treatment option.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122121878A_ABST
    Figure CN122121878A_ABST
Patent Text Reader

Abstract

The present invention relates to a compound for use in the treatment of chronic obstructive pulmonary disease (COPD) in a patient, said compound being encainide or a pharmaceutically acceptable salt thereof, wherein the patient has a blood eosinophil count of < 300 cells / µL.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • DERIVATIVES OF PYRIMIDO[6,1-a]ISOQUINOLIN-4-ONE

    WO2000058308A1

  • New compound and process

    WO2018020249A1